Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 12.3
(1.74%)
INR 12.3
(1.74%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.24 Million INR | -75.32% |
| 2022 | 5.02 Million INR | -50.78% |
| 2021 | 10.2 Million INR | -42.69% |
| 2020 | 17.81 Million INR | 91.94% |
| 2019 | 9.27 Million INR | -5.16% |
| 2018 | 9.78 Million INR | 36.71% |
| 2017 | 7.15 Million INR | 13.28% |
| 2016 | 6.31 Million INR | 56.26% |
| 2015 | 4.04 Million INR | -21.7% |
| 2014 | 5.16 Million INR | 51.8% |
| 2013 | 3.4 Million INR | 25.98% |
| 2012 | 2.69 Million INR | 21.6% |
| 2011 | 2.22 Million INR | 205.41% |
| 2010 | 727 Thousand INR | 325.08% |
| 2009 | -323 Thousand INR | -201.89% |
| 2008 | 317 Thousand INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 510 Thousand INR | 191.43% |
| 2023 Q4 | 175 Thousand INR | -97.83% |
| 2023 Q3 | 8.06 Million INR | 1129.88% |
| 2023 Q2 | 656 Thousand INR | -12.06% |
| 2023 Q1 | 746 Thousand INR | -13.66% |
| 2023 FY | 1.24 Million INR | -75.32% |
| 2022 Q2 | 1.73 Million INR | -1.76% |
| 2022 Q3 | 302 Thousand INR | -82.54% |
| 2022 Q4 | 864 Thousand INR | 186.09% |
| 2022 Q1 | 1.76 Million INR | 234.02% |
| 2022 FY | 5.02 Million INR | -50.78% |
| 2021 Q4 | -1.31 Million INR | -136.95% |
| 2021 Q1 | 3.17 Million INR | -20.15% |
| 2021 Q3 | 3.55 Million INR | 40.11% |
| 2021 Q2 | 2.53 Million INR | -20.14% |
| 2021 FY | 10.2 Million INR | -42.69% |
| 2020 Q2 | 4.71 Million INR | 31.59% |
| 2020 FY | 17.81 Million INR | 91.94% |
| 2020 Q1 | 3.58 Million INR | 60.5% |
| 2020 Q3 | 4.36 Million INR | -7.26% |
| 2020 Q4 | 3.98 Million INR | -8.9% |
| 2019 FY | 9.27 Million INR | -5.16% |
| 2019 Q1 | 1.57 Million INR | -40.29% |
| 2019 Q2 | 2.42 Million INR | 54.55% |
| 2019 Q3 | 2.52 Million INR | 4.04% |
| 2019 Q4 | 2.23 Million INR | -11.7% |
| 2018 Q1 | 2.1 Million INR | -12.09% |
| 2018 FY | 9.78 Million INR | 36.71% |
| 2018 Q4 | 2.63 Million INR | -4.19% |
| 2018 Q3 | 2.74 Million INR | -61.77% |
| 2018 Q2 | 7.18 Million INR | 241.88% |
| 2017 Q2 | 1.82 Million INR | 4.76% |
| 2017 FY | 7.15 Million INR | 13.28% |
| 2017 Q1 | 1.74 Million INR | -45.21% |
| 2017 Q3 | 2.48 Million INR | 35.91% |
| 2017 Q4 | 2.39 Million INR | -3.75% |
| 2016 Q4 | 3.18 Million INR | -13.06% |
| 2016 Q3 | 3.66 Million INR | 931.27% |
| 2016 FY | 6.31 Million INR | 56.26% |
| 2016 Q1 | 497 Thousand INR | -41.46% |
| 2016 Q2 | 355 Thousand INR | -28.57% |
| 2015 Q4 | 849 Thousand INR | 46.13% |
| 2015 FY | 4.04 Million INR | -21.7% |
| 2015 Q3 | 581 Thousand INR | -19.42% |
| 2015 Q2 | 721 Thousand INR | -29.04% |
| 2015 Q1 | 1.01 Million INR | -61.44% |
| 2014 Q3 | 270 Thousand INR | 1100.0% |
| 2014 FY | 5.16 Million INR | 51.8% |
| 2014 Q1 | 1.07 Million INR | -68.5% |
| 2014 Q2 | -27 Thousand INR | -102.52% |
| 2014 Q4 | 2.63 Million INR | 875.8% |
| 2013 Q4 | 3.4 Million INR | 1062.31% |
| 2013 FY | 3.4 Million INR | 25.98% |
| 2013 Q1 | 323 Thousand INR | -81.54% |
| 2013 Q2 | 534 Thousand INR | 65.33% |
| 2013 Q3 | -354 Thousand INR | -166.29% |
| 2012 Q1 | -77 Thousand INR | -168.75% |
| 2012 Q2 | -8000.00 INR | 89.61% |
| 2012 FY | 2.69 Million INR | 21.6% |
| 2012 Q3 | -172 Thousand INR | -2050.0% |
| 2012 Q4 | 1.74 Million INR | 1117.31% |
| 2011 FY | 2.22 Million INR | 205.41% |
| 2011 Q3 | -286 Thousand INR | 0.0% |
| 2011 Q4 | 112 Thousand INR | 139.16% |
| 2010 FY | 727 Thousand INR | 325.08% |
| 2010 Q4 | 404 Thousand INR | 0.0% |
| 2009 Q4 | -18 Thousand INR | 0.0% |
| 2009 FY | -323 Thousand INR | -201.89% |
| 2008 FY | 317 Thousand INR | 0.0% |
| 2008 Q4 | 157 Thousand INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 99.997% |
| Blue Jet Healthcare Limited | 531.85 Million INR | 99.767% |
| Concord Biotech Limited | 1.45 Billion INR | 99.915% |
| Dishman Carbogen Amcis Limited | 5.14 Billion INR | 99.976% |
| FERMENTA BIOTECH LIMITED | 754.2 Million INR | 99.836% |
| GENOMIC VALLEY BIOTECH LIMITED | 375 Thousand INR | -230.667% |
| Lyka Labs Limited | 599.4 Million INR | 99.793% |
| Panacea Biotec Limited | 1.99 Billion INR | 99.938% |
| SAMSRITA LABS LIMITED | 1.49 Million INR | 17.189% |
| Servoteach Industries Limited | 785.00 INR | -157861.783% |
| SMS Lifesciences India Limited | 602.96 Million INR | 99.794% |
| Supriya Lifescience Limited | 1.08 Billion INR | 99.885% |
| Syngene International Limited | 5.99 Billion INR | 99.979% |
| TAKE Solutions Limited | 396.91 Million INR | 99.688% |
| Titan Biotech Limited | 117.05 Million INR | 98.941% |
| Transgene Biotek Limited | 5.39 Million INR | 77.024% |
| Vanta Bioscience Limited | 38.95 Million INR | 96.817% |